Thursday 16 October, 2025
Introduction: Targeted protein degraders (TPDs) are attracting considerable interest with the promise to address disease-related proteins not druggable with inhibitors due…
Read moreOral: Other Topics
Neural ODE structures based on pharmacokinetic principles
Thursday 16 October, 2025
Objectives: Neural ordinary differential equations (NODEs) are a machine learning (ML) approach that can fit data from dynamic systems [1],…
Read moreIntroducing a novel analytical framework for risk stratification of real-world data with survival and unsupervised machine learning. A small cell lung cancer SCLC study
Thursday 16 October, 2025
Objectives: Stratification of patients to predict accurate prognostic outcomes and improve treatment selection is a crucial challenge in oncology [1]….
Read moreBackground on estimands and why are they important?
Thursday 16 October, 2025
The topic of ‘estimands’ is shaking up the biostatistics community as it is at the heart of a draft addendum…
Read moreEvaluation of assumptions underpinning pharmacometric models
Thursday 16 October, 2025
Background: All models are underpinned by assumptions. The validity of any inference drawn from a model depends on the appropriateness and…
Read moreThe new draft EMA Guidance on PBPK – The qualification of the intended use concept
Thursday 16 October, 2025
Objectives: Aspect regarding the Draft EMA PBPK guideline will be presented. Overview/Description of presentation: The use of physiologically based pharmacokinetic (PBPK) modelling…
Read morePerformance of npde for the evaluation of joint model with time to event data
Thursday 16 October, 2025
Objectives: Joint models are increasingly used in clinical trials. An important part of model building is to properly assess the…
Read moreApplication of a linked pharmacometric/pharmacoeconomic model to assess the impact of non-adherence: Application to the treatment of gout
Thursday 16 October, 2025
Introduction A natural extension to pharmacometric analyses, exploiting the structural relationship between dose and response, is to link with pharmacoeconomic…
Read moreSupporting decision making and early prediction of survival for oncology drug development using a pharmacometrics-machine learning based model.
Thursday 16 October, 2025
Introduction: Despite some recent advances in cancer treatment, the attrition rate in late phase studies remains high. Predicting response to…
Read moreModel-based screening of compounds for the treatment of Chagas disease, a neglected tropical disease.
Thursday 16 October, 2025
Objectives: The aim of the investigation was to develop a drug-disease model with suitable parameterisation for the screening and selection…
Read more